ÂÜÀòÂÒÂ×

Thomas Digby is a highly accomplished professional in the field of intellectual property and regulatory affairs, currently serving as Chairperson of the Patented Medicine Prices Review Board in Canada since February 2023. With extensive experience as an attorney for Global IP Asset Management and Clairvoyant Therapeutics Inc., where Thomas is also co-founder and Regulatory & IP Lead, Digby has played significant roles in various organizations, including Novartis as Head of IP Asset Management and Executive Director of IP Licensing. Digby founded Aljadix AG, focusing on carbon-negative biofuels, and has advised on intellectual property matters for multiple startups in the biotech sector. Educational qualifications include a Juris Doctor from Dalhousie University, a Master of Science in Biochemistry, and a Bachelor of Science (Honors) in Biology from Queen's University.